New Therapeutic Opportunities

Given the modularity of our core technology platform we have the ability to generate a large number of medicines across a diverse range of diseases. We will continue to innovate our technology and focus our internal pipeline efforts on therapies where we can create meaningful and differentiated products.

With our GI targeted strategies, we have the ability to access the target-rich tissue of the intestine and directly impact the immune system and other key biological axes. Our bloodstream-targeted strategies further expand our ability to impact a wide array of diseases with not only by providing a more convenient oral form with the potential to also enhance efficacy and safety.

Our core strategic focus is to develop innovative differentiated therapies where we can have maximal benefit in immunology and inflammation, gastroenterology, and metabolic diseases. We are also exploring select strategic collaborations with experienced partners in areas that may be outside our areas of strategic focus, such as diabetes, oncology, or hemophilia.

gi-local
GI Targeted — Local GI Disease
  • UC, Crohn’s, Celiac
  • Short Bowel Syndrome
  • Motility-disorders
  • Fibrosis
  • GIST, CRC
GI-distal
GI Targeted — Distal Disease
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Allergy/Vaccines
  • Parkinson’s Disease
  • Alzheimers Disease
GI-systemic
Bloodstream Targeted — Systemic Disease
  • NASH, Liver Disease
  • Rare Disease
  • Diabetes, Obesity
  • Growth Hormone Deficiency
  • Cancer
  • Hemophilia
  • Psoriasis, Atopic Dermatitis
  • Rheumatoid Arthritis, SLE